Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Lysosomal storage diseases (LSDs) are rare monogenic disorders caused by impaired lysosomal function.
• These diseases affect multiple organ systems and involve complex secondary mechanisms, complicating treatment.
• Current single-modality therapies, including enzyme replacement and gene therapy, often fall short of curative outcomes.

Purpose of the Study:

• To review the efficacy and limitations of singular therapeutic approaches for LSDs.
• To explore the potential of combination therapies for treating LSDs.
• To highlight combination therapy as a promising strategy for holistic disease management.

Main Methods:

• Review of existing literature on singular and combination therapies for LSDs.
• Analysis of studies investigating protein-, cell-, gene-based therapies, and small molecule drugs.
• Evaluation of therapeutic strategies focusing on delivery routes, timing, and targeting secondary mechanisms.

Main Results:

• Singular therapies for LSDs have demonstrated limited success in achieving complete cures.
• Combination approaches, integrating diverse therapeutic modalities, have shown enhanced efficacy in ameliorating disease pathology.
• Studies indicate that combining therapies can lead to more comprehensive improvements in both pathological and functional parameters.

Conclusions:

• Individual therapies for LSDs face significant limitations in achieving curative effects.
• Combination therapy offers a more holistic and effective strategy for managing LSDs.
• Optimizing delivery, timing, and targeting of secondary mechanisms in combination therapies is crucial for future treatment success.